Efficacy and safety of dual therapy - biological and small molecules in patients with ulcerative colitis

Сombination of two or more biological or immunosuppressive drugs in order to achieve a synergistic effect in patients with refractory inflammatory bowel disease (IBD) has been in the spotlight for many years. Combination therapy may include various medications, most often biological and immunosuppressants. Despite the fact that biological therapy of IBD has traditionally focused on drugs that block tumor necrosis factor-alpha, the development of new drugs that act on different targets, such as vedolizumab, ustekinumab, tofacitinib or ozanimod, has made it possible to use combined immunosuppressive therapy. The treatment algorithm suggests various combinations of dual biological therapy for 2 categories of patients with IBD: patients with well-controlled luminal IBD and uncontrolled extra-intestinal symptoms (indications such as arthritis or psoriasis) and patients with refractory, uncontrolled IBD. Thus, data on the efficacy and safety of dual biological therapy as a method of treating Crohn’s disease (CD) or ulcerative colitis (UC) remain very limited. In fact, the vast majority of literature consists of individual cases and a series of cases. Given the lack of studies with a high level of evidence, gastroenterologists have turned to larger studies of dual biological therapy in other areas of medicine, such as rheumatology and dermatology. The aim of this article is to demonstrate clinical experience of combination therapy with genetically engineered biological drugs and selective immunosuppressors in UC, to analyze potential adverse effects or risks associated with combination therapy, and to determine future directions in the use of this treatment.

tumor necrosis factor- alpha, infl ammatory bowel disease (IBD), combination therapy with genetically engineered biological drugs

1. Shelygin Yu.A., Ivashkin V. T., Belousova E. A. et al. Ulcerative colitis (K51), adults. Koloproktologia. 2023;22(1):10-44. (in Russ.) doi: 10.33878/2073-7556-2023-22-1-10-44.@@ Шелыгин Ю. А., Ивашкин В. Т., Белоусова Е. А. и др. Язвенный колит (К51), взрослые. Колопроктология. 2023;22(1):10-44. doi: 10.33878/2073-7556-2023-22-1-10-44.

2. Turner D., Ricciuto A., Lewis A., D’Amico F., Dhaliwal J., Griffiths A. M., Bettenworth D., Sandborn W. J., Sands B. E., Reinisch W., Schölmerich J., Bemelman W., Danese S., Mary J. Y., Rubin D., Colombel J. F., Peyrin-Biroulet L., Dotan I., Abreu M. T., Dignass A.; International Organization for the Study of IBD. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021 Apr;160(5):1570-1583. doi: 10.1053/j.gastro.2020.12.031.

3. Harbord M., Annese V., Vavricka S. R., Allez M., Barreiro-de Acosta M., Boberg K. M., Burisch J., De Vos M., De Vries A. M., Dick A. D., Juillerat P., Karlsen T. H., Koutroubakis I., Lakatos P. L., Orchard T., Papay P., Raine T., Reinshagen M., Thaci D., Tilg H., Carbonnel F.; European Crohn’s and Colitis Organisation. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis. 2016 Mar;10(3):239-54. doi: 10.1093/ecco-jcc/jjv213.

4. Belousova E.A., Shelygin Yu.A., Achkasov S. I. et al. Clinical and Demographic Features and Treatment Approaches for Inflammatory Bowel Diseases (Crohn’s Disease, Ulcerative Colitis) in the Russia. The Primery Results of the Analysis of the National Register. Koloproktologia. 2023;22(1):65-82. (in Russ.) doi: 10.33878/2073-7556-2023-22-1-65-82.@@ Белоусова Е. А., Шелыгин Ю. А., Ачкасов С. И. и Соавт. Клинико-демографические характеристики и лечебные подходы у пациентов с воспалительными заболеваниями кишечника (болезнь Крона, язвенный колит) в РФ. Первые результаты анализа национального Регистра. Колопроктология. 2023;22(1):65-82. doi: 10.33878/2073-7556-2023-22-1-65-82.

5. McDonnell M., Harris R. J., Borca F., Mills T. et al. High incidence of glucocorticoid-induced hyperglycaemia in inflammatory bowel disease: metabolic and clinical predictors identified by machine learning. BMJ Open Gastroenterol. 2020 Nov;7(1): e000532. doi: 10.1136/bmjgast-2020-000532.

6. Graham D.B., Xavier R. J. Pathway paradigms revealed from the genetics of inflammatory bowel disease. Nature. 2020 Feb;578(7796):527-539. doi: 10.1038/s41586-020-2025-2.

7. Privitera G., Pugliese D., Lopetuso L. R., Scaldaferri F., Neri M., Guidi L., Gasbarrini A., Armuzzi A. Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches. Therap Adv Gastroenterol. 2021 Apr 27;14:17562848211006669. doi: 10.1177/17562848211006669.

8. Alayo Q.A., Fenster M., Altayar O. et al. Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease. Crohns Colitis 360. 2022 Feb 10;4(1): otac002. doi: 10.1093/crocol/otac002.

9. Abreu M. T.Combining Biologic Agents in Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2019 Oct;15(10):549-551. PMID: 31802979

10. Gold S.L., Steinlauf A. F. Efficacy and Safety of Dual Biologic Therapy in Patients With Inflammatory Bowel Disease: A Review of the Literature. Gastroenterol Hepatol (N Y). 2021 Sep;17(9):406-414. PMID: 34602905

11. Sands B.E., Kozarek R., Spainhour J., Barish C. F., Becker S., Goldberg L., Katz S., Goldblum R., Harrigan R., Hilton D., Hanauer S. B. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn’s disease not in remission while receiving infliximab. Inflamm Bowel Dis. 2007 Jan;13(1):2-11. doi: 10.1002/ibd.20014.

12. Ahmed W., Galati J., Kumar A., Christos P. J., Longman R., Lukin D. J., Scherl E., Battat R. Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022 Mar;20(3): e361-e379. doi: 10.1016/j.cgh.2021.03.034.

13. Balderramo D. Role of the combination of biologics and/or small molecules in the treatment of patients with inflammatory bowel disease. World J Gastroenterol. 2022 Dec 21;28(47):6743-6751. doi: 10.3748/wjg.v28.i47.6743.

14. Ribaldone D.G., Pellicano R., Vernero M., Caviglia G. P., Saracco G. M., Morino M., Astegiano M. Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis. Scand J Gastroenterol. 2019 Apr;54(4):407-413. doi: 10.1080/00365521.2019.1597159.

15. Mas E.B., Calvo X. C. Selecting the Best Combined Biological Therapy for Refractory Inflammatory Bowel Disease Patients. J Clin Med. 2022 Feb 18;11(4):1076. doi: 10.3390/jcm11041076.

16. Guillo L., Flachaire B., Avouac J. et al.; COMBIO Study Group. Efficacy and safety of combination targeted therapies in immune-mediated inflammatory disease: the COMBIO study. Dig Liver Dis. 2023 Jan;55(1):61-68. doi: 10.1016/j.dld.2022.07.012.

17. Goessens L., Colombel J. F., Outtier A. et al.; European COMBIO study group; Rahier JF. Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study. United European Gastroenterol J. 2021 Dec;9(10):1136-1147. doi: 10.1002/ueg2.12170.